Nomenclature
CAS number: 71486-22-1
(2β,3β,4β,5α,12
R,19α)-4-(Acetyloxy)-6,7-didehydro-15-[(2
R,6
R,8
S)-4-ethyl-1,3,6,7,8,9-hexahydro-8-(methoxycarbonyl)-2,6-methano-2
H-azecino[4,3-
b]indol-8-yl]-3-hydroxy-16-methoxy-1-methylaspidospermidine-3-carboxylic
acid methyl ester; 3′,4′-didehydro-4′-deoxy-
C′-norvincaleukoblastine; nor-5′-anhydrovinblastine; NVB; KW-2307.
C
45H
54N
4O
8; mol wt 778.93.
C 69.39%, H 6.99%, N 7.19%, O 16.43%.
Description and references
Semi-synthetic Vinca alkaloid; structurally
related to vinblastine, q.v. Prepn: JP Kokai 80 31096; N. Langlois et al., US 4307100 (1980, 1981 both to Agence Nat. Valorisation Recherche); P. Mangeney et al., Tetrahedron 35, 2175 (1979). Pharmacology: G. Mathé, P. Reizenstein, Cancer Lett. 27, 285 (1985).
HPLC determn in biological fluids: F. Jehl et al., J. Chromatogr. 525, 225 (1990).
Veterinary trial in dogs with spontaneous neoplasia: V. J. Poirier et al., J. Vet. Intern. Med. 18, 536 (2004). Symposium: Semin. Oncol. 16, Suppl. 4, 1-45 (1989).
Review of early clinical development: M. Marty et al., Nouv. Rev. Fr. Hematol. 31, 77-84 (1989); of clinical pharmacokinetics: D. Leveque,
F. Jehl, Clin. Pharmacokinet. 31, 184-197 (1996); of use in advanced non-small cell lung
cancer: M. P. Curran, G. L. Plosker, Drugs
Aging 19, 695-721 (2002).
Properties
Residue. [α]D20 +52.4° (c = 0.3 in CHCl3). uv max (ethanol): 215, 268, 282, 293, 310 nm (ε 3700, 11000, 9500, 7600, 4400). Partition coefficient (octanol/buffer
pH 7.2): 16. LD50 in mice (mg/m2): 72 i.v.; 78 orally (Mathé, Reizenstein).Derivative
Ditartrate.
Nomenclature
CAS number: 125317-39-7
Eunades (Pfizer); Navelbine (Fabre).
C
45H
54N
4O
8.2C
4H
6O
6; mol wt 1079.11.
C 58.99%, H 6.16%, N 5.19%, O 29.65%.
Properties
Yellow-white amorphous powder. Sol in water and
ethanol.Therapeutic Category
Antineoplastic.
Therapeutic Category (Veterinary)
Antineoplastic.
Keywords
Antineoplastic; Alkaloids/Natural Products; Vinca Alkaloids